JP7387179B2 - 発達障害の処置における(s)-3-アミノ-4-(ジフルオロメチレニル)シクロペンタ-1-エン-1-カルボン酸および関連化合物、(1s,3s)-3-アミノ-4-(ジフルオロメチリデン)シクロペンタン-1-カルボン酸ならびにビガバトリンの使用 - Google Patents

発達障害の処置における(s)-3-アミノ-4-(ジフルオロメチレニル)シクロペンタ-1-エン-1-カルボン酸および関連化合物、(1s,3s)-3-アミノ-4-(ジフルオロメチリデン)シクロペンタン-1-カルボン酸ならびにビガバトリンの使用 Download PDF

Info

Publication number
JP7387179B2
JP7387179B2 JP2020567857A JP2020567857A JP7387179B2 JP 7387179 B2 JP7387179 B2 JP 7387179B2 JP 2020567857 A JP2020567857 A JP 2020567857A JP 2020567857 A JP2020567857 A JP 2020567857A JP 7387179 B2 JP7387179 B2 JP 7387179B2
Authority
JP
Japan
Prior art keywords
day
pharmaceutically acceptable
acceptable salt
amino
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020567857A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527053A5 (cg-RX-API-DMAC10.html
JP2021527053A (ja
Inventor
マシュー・デューリング
ブレット・エイブラハムズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of JP2021527053A publication Critical patent/JP2021527053A/ja
Publication of JP2021527053A5 publication Critical patent/JP2021527053A5/ja
Application granted granted Critical
Publication of JP7387179B2 publication Critical patent/JP7387179B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2020567857A 2018-06-07 2019-06-07 発達障害の処置における(s)-3-アミノ-4-(ジフルオロメチレニル)シクロペンタ-1-エン-1-カルボン酸および関連化合物、(1s,3s)-3-アミノ-4-(ジフルオロメチリデン)シクロペンタン-1-カルボン酸ならびにビガバトリンの使用 Active JP7387179B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862681913P 2018-06-07 2018-06-07
US62/681,913 2018-06-07
PCT/US2019/035934 WO2019236938A1 (en) 2018-06-07 2019-06-07 Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders

Publications (3)

Publication Number Publication Date
JP2021527053A JP2021527053A (ja) 2021-10-11
JP2021527053A5 JP2021527053A5 (cg-RX-API-DMAC10.html) 2022-06-14
JP7387179B2 true JP7387179B2 (ja) 2023-11-28

Family

ID=68765508

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020567857A Active JP7387179B2 (ja) 2018-06-07 2019-06-07 発達障害の処置における(s)-3-アミノ-4-(ジフルオロメチレニル)シクロペンタ-1-エン-1-カルボン酸および関連化合物、(1s,3s)-3-アミノ-4-(ジフルオロメチリデン)シクロペンタン-1-カルボン酸ならびにビガバトリンの使用

Country Status (12)

Country Link
US (3) US10813899B2 (cg-RX-API-DMAC10.html)
EP (1) EP3813816B1 (cg-RX-API-DMAC10.html)
JP (1) JP7387179B2 (cg-RX-API-DMAC10.html)
KR (1) KR102744830B1 (cg-RX-API-DMAC10.html)
CN (1) CN112770739B (cg-RX-API-DMAC10.html)
AU (1) AU2019280980B2 (cg-RX-API-DMAC10.html)
CA (1) CA3102786A1 (cg-RX-API-DMAC10.html)
ES (1) ES2948263T3 (cg-RX-API-DMAC10.html)
IL (2) IL279220B2 (cg-RX-API-DMAC10.html)
MX (2) MX2020013290A (cg-RX-API-DMAC10.html)
PL (1) PL3813816T3 (cg-RX-API-DMAC10.html)
WO (1) WO2019236938A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019236938A1 (en) 2018-06-07 2019-12-12 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
WO2020039262A1 (en) 2018-08-18 2020-02-27 Ftf Pharma Private Limited Pharmaceuticals solution for oral dosage
WO2024058812A1 (en) 2022-09-16 2024-03-21 Pyros Pharmaceuticals, Inc. Vigabatrin liquid pharmaceutical composition
IL322802A (en) 2023-02-17 2025-10-01 Ovid Therapeutics Inc Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of gastrointestinal disorders and as an immunomodulatory agent
US20240285565A1 (en) 2023-02-17 2024-08-29 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of diabetes and pre-diabetes
US20260130878A1 (en) * 2024-11-12 2026-05-14 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of pain

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794413B1 (en) 2002-07-19 2004-09-21 Northwestern University Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase
WO2005120496A2 (en) 2004-05-24 2005-12-22 Regents Of The University Of California TREATING LEARNING DEFICITS WITH INHIBITORS OF HMG CoA REDUCTASE
WO2009033818A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
CA2790820A1 (en) 2010-02-25 2011-09-01 Northwestern University Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor
US20130230586A1 (en) 2010-10-02 2013-09-05 Link Research & Grants Corporation Treatment of Tinnitus and Related Auditory Dysfunctions
WO2013006857A1 (en) 2011-07-07 2013-01-10 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism
WO2013112363A1 (en) 2012-01-27 2013-08-01 Catalyst Pharmaceutical Partners Method of treating tourette's disorder with gaba-aminotransferase inactivators
TW201606304A (zh) * 2013-09-09 2016-02-16 亞克柏拉有限公司 測定治療反應之方法
US20150224164A1 (en) 2013-11-26 2015-08-13 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid
AU2015342801A1 (en) 2014-11-07 2017-05-18 Hadasit Medical Research Services And Development Ltd. Ornithine aminotransferase inhibition with GABA Analogues for treatment of hepatocellular carcinoma
US20170348232A1 (en) * 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
CN108137484B (zh) * 2015-10-09 2021-02-12 西北大学 作为用于治疗癫痫、成瘾和肝细胞癌的gaba氨基转移酶灭活剂的化合物
US10632088B2 (en) 2016-10-10 2020-04-28 Northwestern University Inactivators of Toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria
KR20240110989A (ko) * 2017-02-08 2024-07-16 오비드 테라퓨틱스 인크. 프라더-윌리 증후군 및 발작 장애들을 치료하는 방법들
US20200268711A1 (en) * 2017-11-14 2020-08-27 Sk Biopharmaceuticals Co., Ltd. Use Of Carbamate Compound For Reducing Or Treating Developmental Disorders Including Fragile X Syndrome, Angelman Syndrome Or Rett Syndrome
JP7475055B2 (ja) 2018-05-25 2024-04-26 ノースウェスタン ユニバーシティ (s)-3-アミノ-4-(ジフルオロメチレニル)シクロペンタ-1-エン-1-カルボン酸の合成法
WO2019236938A1 (en) 2018-06-07 2019-12-12 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Genes,2016年,Vol.7,45 (page 1-13)
J. Am. Chem. Soc.,2018年01月,Vol.140,pp.2151-2164

Also Published As

Publication number Publication date
MX2020013290A (es) 2021-04-29
KR102744830B1 (ko) 2024-12-19
IL304270B2 (en) 2024-10-01
US20190374492A1 (en) 2019-12-12
IL304270B1 (en) 2024-06-01
IL279220B2 (en) 2023-12-01
KR20210035802A (ko) 2021-04-01
EP3813816A1 (en) 2021-05-05
CA3102786A1 (en) 2019-12-12
IL304270A (en) 2023-09-01
CN112770739B (zh) 2023-12-12
IL279220A (en) 2021-01-31
US11660277B2 (en) 2023-05-30
IL279220B1 (en) 2023-08-01
EP3813816A4 (en) 2021-06-23
US12285397B2 (en) 2025-04-29
AU2019280980B2 (en) 2025-02-27
EP3813816B1 (en) 2023-06-07
US10813899B2 (en) 2020-10-27
CN112770739A (zh) 2021-05-07
AU2019280980A1 (en) 2021-01-07
MX2023006497A (es) 2023-06-21
JP2021527053A (ja) 2021-10-11
WO2019236938A1 (en) 2019-12-12
US20230255914A1 (en) 2023-08-17
US20210100763A1 (en) 2021-04-08
EP3813816C0 (en) 2023-06-07
PL3813816T3 (pl) 2023-07-31
ES2948263T3 (es) 2023-09-07

Similar Documents

Publication Publication Date Title
US12285397B2 (en) Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
ES2367868T3 (es) Uso de memantina (namenda) para tratar el autismo, la compulsividad y la impulsividad.
AU2019216742B2 (en) Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction
EP3579826B1 (en) Methods of treating cdkl5 disorders with the compound ov329
CA2667924A1 (en) The use of pramipexole or a salt thereof for the treatment of parkinson's disease
US20190298740A1 (en) Methods and compositions for treating hallucinations and conditions related to the same
JP2021500377A (ja) 遅延放出デフェリプロン錠剤及びその使用法
JPWO2008090736A1 (ja) アルツハイマー型認知症の予防及び治療のための医薬
WO2020018779A1 (en) Use of phenylethylidenehydrazine to treat seizure disorders, developmental disorders, neurological disorders, behavioral disorders and addiction
US11771671B2 (en) Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction
HK40050398A (en) Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid in the treatment of fragile x syndrome or fragile x-associated tremor/ataxia syndrome
HK40050398B (en) Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid in the treatment of fragile x syndrome or fragile x-associated tremor/ataxia syndrome
CN112930182A (zh) 加波沙朵用于治疗图雷特综合征、抽搐和口吃的用途
HK40012437A (en) Methods of treating developmental disorders and/or seizure disorders with flupirtine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220606

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220606

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230509

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231010

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231108

R150 Certificate of patent or registration of utility model

Ref document number: 7387179

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150